Skip to main content
Search
Main content
Nature aging
Published

Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer's disease pathology

Authors

Jun-Ping Pan, Ping-Jie Wang, Jianying Zhang, Anne-Brita Knapskog, Leiv Otto Watne, He-Ling Wang, Maria Jose Lagartos-Donate, Sofie Lautrup, Li-Peng Mao, Qian Wang, Zhi-Peng Ling, Shi-Qi Zhang, Tomás Schmauck-Medina, Ruixue Ai, Trine Holt Edwin, Tianjiao Zhang, Ingvild Saltvedt, Rannveig Sakshaug Eldholm, Annabel Smith, Kateřina Veverová, Domenica Caponio, Asgeir Kobro-Flatmoen, Huanhuan Pang, Zijian Wang, Haoyun Wang, Li-Juan Gao, Nathalie Bodd Halaas, Garry Wong, Martin Vyhnalek, Oscar Junhong Luo, William A McEwan, Jon Storm-Mathisen, Li Gan, Zeping Hu, Henrik Zetterberg, Menno P Witter, Dag Aarsland, Geir Selbæk, Guobing Chen, Evandro Fei Fang

Abstract

Nat Aging. 2026 May 14. doi: 10.1038/s43587-026-01108-z. Online ahead of print.

ABSTRACT

ULK1 (Atg1) initiates macroautophagy and mitophagy, which support neuronal growth and survival, yet how this pathway is disrupted in aging and Alzheimer's disease (AD) remains unclear. Here we report reduced ULK1 in serum and cerebrospinal fluid during aging in cognitively unimpaired participants from the COGNORM study (n = 75) and in patients with AD from the NorCog Memory Clinic Cohort (n = 316). In AD mice, ULK1 overexpression stimulates autophagic flux, reduces AD pathology and delays cognitive decline alongside increased phagocytic degradation of amyloid-β, reduced tauopathy and improved mitochondrial quality. Mechanistically, ULK1 upregulation increases autophagy and PINK1-, FUNDC1- and AMBRA1-associated mitophagy; higher autophagy and mitophagy increase cellular NAD+, which in turn deacetylates acetylated-Tau174 via the NAD+-SIRT1 axis, leading to reduced tauopathy. Using in vitro tau seeding assays and a Caenorhabditis elegans tau model, we validate the efficacy of ULK1 activators in inhibiting tauopathy. We propose that age-related decline in ULK1 leads to autophagy and mitophagy impairment and increases the progression of AD and identify ULK1 as a potential therapeutic target.

PMID:42135576 | DOI:10.1038/s43587-026-01108-z

UK DRI Authors

Annabel Smith

Research Assistant

Investigating how antibody epitope location determines TRIM21-medited intracellular neutralisation of tau assemblies.

Annabel Smith

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg
Dag Arsland profile

Prof Dag Aarsland

UK DRI Affiliate Member

Director of the Centre for Healthy Brain Ageing, King's College London

Prof Dag Aarsland